Genetics and Cytogenetics of Multiple Myeloma: A Workshop Report

Cancer Research

Volumn 64, Issue 4, 2004, Pages 1546-1558

  Fonseca, Rafael ^a,k   Barlogie, Bart ^b   Bataille, Regis ^c   Bastard, Christian ^c   Bergsagel, P Leif ^d   Chesi, Marta ^d   Davies, Faith E ^e   Drach, Johannes ^f   Greipp, Philip R ^a   Kirsch, Ilan R ^g   Kuehl, W Michael ^g   Hernandez, Jesus M ^h   Minvielle, Stephane ^c   Pilarski, Linda M ⁱ   Shaughnessy Jr , John D ^b   Stewart, A Keith ^j   Avet Loiseau, Herve ^c,l  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c INSTITUT DE BIOLOGIE   (France)

^d WEILL CORNELL MEDICAL CENTER   (United States)

^e UNIVERSITY OF LEEDS   (United Kingdom)

^f UNIVERSITY OF VIENNA   (Austria)

^g NATIONAL CANCER INSTITUTE   (United States)

^h HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

ⁱ UNIVERSITY OF ALBERTA   (Canada)

^j PRINCESS MARGARET HOSPITAL   (Canada)

^k MAYO CLINIC   (United States)

^l NANTES UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYTOKINE; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; INTERLEUKIN 6; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RETINOBLASTOMA PROTEIN; RNA;

ANEUPLOIDY; BONE MARROW EXAMINATION; CHROMOSOME TRANSLOCATION; CONFERENCE PAPER; CYTOGENETICS; DNA MICROARRAY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOCUS; GENE MUTATION; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; KARYOTYPE; MAJOR CLINICAL STUDY; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; ONCOGENE; ONCOGENE MYC; ONCOGENE RAS; PATHOGENESIS; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS;

ANEUPLOIDY; BONE MARROW EXAMINATION; CHROMOSOME ABERRATIONS; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IN SITU HYBRIDIZATION, FLUORESCENCE; MULTIPLE MYELOMA; MUTATION; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TRANSLOCATION, GENETIC;

EID: 10744223381     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-2876     Document Type: Conference Paper

References (166)

1. Dewald, G. W., Kyle, R. A., Hicks, G. A., and Greipp, P. R. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma plasma cell leukemia, or amyloidosis. Blood, 66: 380-390, 1985.
2. Zandecki, M., Lai, J. L., and Facon, T. Multiple myeloma: almost all patients are cytogenetically abnormal. Br. J. Haematol., 94: 217-227, 1996.
3. Tabernero, D., San Miguel, J. F., Garcia-Sanz, M., Najera, L., Garcia-Isidoro, M., Perez-Simon, J. A., Gonzalez, M., Wiegant, J., Raap, A. K., and Orfao, A. Incidence of chromosome numerical changes in multiple myeloma: fluorescence in situ hybridization analysis using 15 chromosome-specific probes. Am. J. Pathol., 149: 153-161, 1996.
4. Avet-Loiseau, H., Facon, T., Grosbois, B., Magrangeas, F., Rapp, M. J., Harousseau, J. L., Minvielle, S., Bataille, R., and Intergroupe Francophone du Myelome. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood, 99: 2185-2191, 2002.
5. Drach, J., Schuster, J., Nowotny, H., Angerler, J., Rosenthal, F., Fiegl, M., Rothermundt, C., Gsur, A., Jager, U., Heinz, R., Lechner, K., Ludwig, H., and Huber, H. Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization. Cancer Res., 55: 3854-3859, 1995.
6. Fonseca, R., Ahmann, G. J., Juneau, A. L., Jalal, S. M., Dewald, G. W., Larson, D. M., Therneau, T. M., Gertz, M. A., and Greipp, P. R. Cytogenetic abnormalities in multiple myeloma and related plasma cell disorders; a comparison of conventional cytogenetic analysis to fluorescent in-situ hybridization with simultaneous cytoplasmic immunoglobulin staining (Meeting Abstract). Blood, 90: 349, 1997.
7. Fonseca, R., Bailey, R. J., Ahmann, G. J., Rajkumar, S. V., Hoyer, J. D., Lust, J. A., Kyle, R. A., Gertz, M. A., Greipp, P. R., and Dewald, G. W. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood, 100: 1417-1424, 2002.
8. Kuehl, W. M., and Bergsagel, P. L. Multiple myeloma: evolving genetic events and host interactions. Nat. Rev Cancer, 2: 175-187, 2002.
9. Bergsagel, P. L., and Kuehl, W. M. Chromosome translocations in multiple myeloma. Oncogene, 20: 5611-5622, 2001.
10. Tricot, G., Barlogie, B., Jagannath, S., Bracy, D., Mattox, S., Vesole, D. H., Naucke, S., and Sawyer, J. R. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood, 86: 4250-4256, 1995.
11. Smadja, N. V., Bastard, C., Brigaudeau, C., Leroux, D., and Fruchart, C. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood, 98: 2229-2238, 2001.
12. Smadja, N. V., Fruchart, C., Isnard, F., Louvet, C., Dutel, J. L., Cheron, N., Grange, M. J., Monconduit, M., and Bastard, C. Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia (Baltimore), 12: 960-969, 1998.
13. Seong, C., Delasalle, K., Hayes, K., Weber, D., Dimopoulos, M., Swantkowski, J., Huh, Y., Glassman, A., Champlin, R., and Alexanian, R. Prognostic value of cytogenetics in multiple myeloma. Br. J. Haematol., 101: 189-194, 1998.
14. Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., and Melton, L. J., III. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. [See comments.]. N. Eng. J. Med., 346: 564-569, 2002.
15. International-Myeloma-Working-Group Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br. J. Haematol., 121: 749-757, 2003.
16. Rajkumar, S. V., Fonseca, R., Dewald, G. W., Therneau, T. M., Lacy, M. Q., Kyle, R. A., Greipp, P. R., and Gertz, M. A. Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. Cancer Genet Cytogenet., 113: 73-77, 1999.
17. Cesana, C., Klersy, C., Barbarano, L., Nosari, A. M., Crugnola, M., Pungolino, E., Gargantini, L., Granata, S., Valentini, M., and Morra, E. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J. Clin. Oncol., 20: 1625-1634, 2002.
18. Salmon, S. Immunoglobulin synthesis and tumor kinetics of multiple myeloma. Semin. Hematol., 10: 135-147, 1973.
19. Bergsagel, D. The incidence and epidemiology of plasma cell neoplasms. Stem Cells (Dayton), 13 (Suppl. 2): 1-9, 1995.
20. Avet-Loiseau, H., Facon, T., Daviet, A., Godon, C., Rapp, M. J., Harousseau, J. L., Grosbois, B., and Bataille, R. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome. Cancer Res., 59: 4546-4550, 1999.
21. Drach, J., Angerler, J., Schuster, J., Rothermundt, C., Thalhammer, R., Haas, O. A., Jager, U., Fiegl, M., Geissler, K., and Ludwig, H. Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. Blood, 86: 3915-3921, 1995.
22. Zandecki, M., Obein, V., Bernardi, F., Soenen, V., Flactif, M., Lai, J. L., Francois, M., and Facon, T. Monoclonal gammopathy of undetermined significance: chromosome changes are a common finding within bone marrow plasma cells. Br. J. Haematol., 90: 693-696, 1995.
23. Rasillo, A., Tabernero, M. D., Sanchez, M. L., Perez de Andres, M., Martin Ayuso, M., Hernandez, J., Moro, M. J., Fernandez-Calvo, J., Sayagues, J. M., Bortoluci, A., San Miguel, J. F., and Orfao, A. Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia. Cancer (Phila.), 97: 601-609, 2003.
24. Kyle, R. A., and Garton, J. P. The spectrum of IgM monoclonal gammopathy in 430 cases. Mayo Clin. Proc., 62: 719-731, 1987.
25. Kyle, R. A., and Greipp, P. R. Smoldering multiple myeloma. N. Engl. J. Med., 302: 1347-1349, 1980.
26. Witzig, T. E., Kyle, R. A., O'Fallon, W. M., and Greipp, P. R. Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma. Br. J. Haematol., 87: 266-272, 1994.
27. Blade, J., Lopez, G. A., Rozman, C., Cervantes, F., Salgado, C., Aguilar, J. L., Vives, C. J. L., and Montserrat, E. Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance. Br. J. Haematol., 81: 391-394, 1992.
28. Bataille, R., and Harousseau, J. L. Multiple myeloma. N. Engl. J. Med., 336: 1657-1664, 1997.
29. Avet-Loiseau, H., Li, J. Y., Morineau, N., Facon, T., Brigaudeau, C., Harousseau, J. L., Grosbois, B., and Bataille, R. Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myelome. Blood, 94: 2583-2589, 1999.
30. Colls, B. M. Monoclonal gammopathy of undetermined significance (MGUS) -31 year follow up of a community study. Aust. N. Z. J. Med., 29: 500-504, 1999.
31. Zhan, F., Tian, E., Bumm, K., Smith, R., Barlogie, B., and Shaughnessy, J., Jr. Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood, 101: 1128-1140, 2003.
32. Jourdan, M., Ferlin, M., Legouffe, E., Horvathova, M., Liautard, J., Rossi, J. F., Wijdenes, J., Brochier, J., and Klein, B. The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br. J. Haematol., 100: 637-646, 1998.
33. Ahmann, G. J., Jalal, S. M., Juneau, A. L., Christensen, E. R., Hanson, C. A., Dewald, G. W., and Greipp, P. R. A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies. Cancer Genet Cytogenet., 101: 7-11, 1998.
34. Lai, J. L., Zandecki, M., Mary, J. Y., Bernardi, F., Izydorezyk, V., Flactif, M., Morel, P., Jouet, J. P., Bauters, F., and Facon, T. Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. [Review]. Blood, 85: 2490-2497, 1995.
35. Gould, J., Alexanian, R., Goodacre, A., Pathak, S., Hecht, B., and Barlogie, B. Plasma cell karyotype in multiple myeloma. Blood, 71: 453-456, 1988.
36. Zandecki, M. Multiple-myeloma-almost all patients are cytogenetically abnormal. Br. J. Haematol., 94: 217-227, 1996.
37. Sawyer, J. R., Waldron, J. A., Jagannath, S., and Barlogie, B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet., 82: 41-49, 1995.
38. Debes-Marun, C., Dewald, G., Bryant, S., Picken, E., Santana-Dá vila, S., González-Paz, N., Winkler, J. M., Kyle, R., Gertz, M., Witzig, T., Dispenzieri, A., Lacy, M., Rajkumar, S., Lust, J., Greipp, P., and Fonseca, R. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia (Baltimore), 17: 427-436, 2003.
39. Chesi, M., Nardini, E., Brents, L. A., Schrock, E., Ried, T., Kuehl, W. M., and Bergsagel, P. L. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat. Genet., 16: 260-264, 1997.
40. Chesi, M., Bergsagel, P. L., Shonukan, O. O., Martelli, M. L., Brents, L. A., Chen, T., Schrock, E., Ried, T., and Kuehl, W. M. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood, 91: 4457-4463, 1998.
41. Sawyer, J. R., Lukacs, J. L., Munshi, N., Desikan, K. R., Singhal, S., Mehta, J., Siegel, D., Shaughnessy, J., and Barlogie, B. Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping. Blood, 92: 4269-4278, 1998.
42. Sawyer, J. R., Lukacs, J. L., Thomas, E. L., Swanson, C. M., Goosen, L. S., Sammartino, G., Gilliland, J. C., Munshi, N. C., Tricot, G., Shaughnessy, J. D., Jr., and Barlogie, B. Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma. Br. J. Haematol. 112: 167-174, 2001.
43. Rao, P. H., Cigudosa, J. C., Ning, Y., Calasanz, M. J., Iida, S., Tagawa, S., Michaeli, J., Klein, B., Dalla-Favera, R., Jhanwar, S. C., Ried, T., and Chaganti, R. S. Multicolor spectral karyotyping identifies new recurring breakpoints and translocations in multiple myeloma. Blood, 92: 1743-1748, 1998.
44. Avet-Loiseau, H., and Bataille, R. Detection of nonrandom chromosomal changes in multiple myeloma by comparative genomic hybridization. Blood, 92: 2997-2998, 1998.
45. Cigudosa, J. C., Rao, P. H., Calasanz, M. J., Odero, M. D., Michaeli, J., Jhanwar, S. C., and Chaganti, R. S. Characterization of nonrandom chromosomal gains and losses in multiple myeloma by comparative genomic hybridization. Blood, 91: 3007-3010, 1998.
46. Gutierrez, N. C., Hernandez, J. M., Garcia, J. L., Canizo, M. C., Gonzalez, M., Hernandez, J., Gonzalez, M. B., Garcia-Marcos, M. A., and San Miguel, J. F. Differences in genetic changes between multiple myeloma and plasma cell leukemia demonstrated by comparative genomic hybridization. Leukemia (Baltimore), 15: 840-845, 2001.
47. Avet-Loiseau, H., Andree-Ashley, L. E., Moore, D., II, Mellerin, M. P., Feusner, J., Bataille, R., and Pallavicini, M. G. Molecular cytogenetic abnormalities in multiple myeloma and plasma cell leukemia measured using comparative genomic hybridization. Genes Chromosomes Cancer, 19: 124-133, 1997.
48. Hayman, S. R., Bailey, R. J., Jalal, S. M., Ahmann, G. J., Dispenzieri, A., Gertz, M. A., Greipp, P. R., Kyle, R. A., Lacy, M. Q., Rajkumar, V., Witzig, T. E., Lust, J. A., and Fonseca, R. Translocations involving heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis. Blood, 98: 2266-2268, 2001.
49. Fonseca, R., Harrington, D., Oken, M., Kyle, R., Dewald, G., Bailey, R., Van Wier, S., Henderson, K., Hoyer, J., Blood, E., Kay, N., Van Ness, B., and Greipp, P. Myeloma and the t(11;14)(q13;q32) represents a uniquely defined biological subset of patients. Blood, 99: 3735-3741, 2002.
50. Fonseca, R., Harrington, D., Oken, M., Dewald, G., Bailey, R., Van Wier, S., Henderson, K., Blood, E., Rajkumar, S., Kay, N., Van Ness, B., and Greipp, P. Biologic and prognostic significance of interphase FISH detection of chromosome 13 abnormalities (Δ13) in multiple myeloma: an Eastern Cooperative Oncology Group (ECOG) Study. Cancer Res., 62: 715-720, 2002.
51. Fonseca, R., Oken, M., and Greipp, P. The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathies of undetermined significance. Blood, 98: 1271-1272, 2001.
52. Fonseca, R., Oken, M., Harrington, D., Bailey, R., Van Wier, S., Henderson, K., Kay, N., Van Ness, B., Greipp, P., and Dewald, G. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q-arm or monosomy. Leukemia (Baltimore), 15: 981-986, 2001.
53. Fonseca, R., Blood, E., Rue, M., Harrington, D., Oken, M. M., Kyle, R. A., Dewald, G. W., Van Ness, B., Van Wier, S. A., Henderson, K. J., Bailey, R. J., and Greipp, P. R. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood, 101: 4569-4575, 2003.
54. Avet-Loiseau, H., Brigaudeau, C., Morineau, N., Talmant, P., Lai, J. L., Daviet, A., Li, J. Y., Praloran, V., Rapp, M. J., Harousseau, J. L., Facon, T., and Bataille, R. High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization. Genes Chromosomes Cancer, 24: 9-15, 1999.
55. Avet-Loiseau, H., Daviet, A., Saunier, S., and Bataille, R. Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13. Br. J. Haematol., 111: 1116-1117, 2000.
56. Avet-Loiseau, H., Li, J. Y., Facon, T., Brigaudeau, C., Morineau, N., Maloisel, F., Rapp, M. J., Talmant, P., Trimoreau, F., Jaccard, A., Harousseau, J. L., and Bataille, R. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32). Cancer Res., 58: 5640-5645, 1998.
57. Konigsberg, R., Ackermann, J., Kaufmann, H., Zojer, N., Urbauer, E., Kromer, E., Jager, U., Gisslinger, H., Schreiber, S., Heinz, R., Ludwig, H., Huber, H., and Drach, J. Deletions of chromosome 13q in monoclonal gammopathy of undetermined significance. Leukemia (Baltimore), 14: 1975-1979, 2000.
58. Fonseca, R., Ahmann, G. J., Jalal, S. M., Dewald, G. W., Larson, D. R., Therneau, T. M., Gertz, M. A., Kyle, R. A., and Goipp, P. R. Chromosomal abnormalities in systemic amyloidosis. Br. J. Haematol., 103: 704-710, 1998.
59. Gabrea, A., Bergsagel, P. L., Chesi, M., Shou, Y., and Kuehl, W. M. Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell. Mol. Cell, 3: 119-123, 1999.
60. Keats, J. J., Reiman, T., Maxwell, C. A., Taylor, B. J., Larratt, L. M., Mant, M. J., Belch, A. R., and Pilarski, L. M. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood, 101: 1520-1529, 2003.
61. Santra, M., Zhan, F., Tian, E., Barlogie, B., and Shaughnessy, J., Jr. A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood, 101: 2374-2376, 2003.
62. Zhan, F., Hardin, J., Kordsmeier, B., Bumm, K., Zheng, M., Tian, E., Sanderson, R., Yang, Y., Wilson, C., Zangari, M., Anaissie, E., Morris, C., Muwalla, F., van Rhee, F., Fassas, A., Crowley, J., Tricot, G., Barlogie, B., and Shaughnessy, J., Jr. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood, 99: 1745-1757, 2002.
63. De Vos, J., Couderc, G., Tarte, K., Jourdan, M., Requirand, G., Delteil, M-C., Rossi, J-F., Mechti, N., and Klein, B. Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. Blood, 98: 771-780, 2001.
64. Tarte, K., De Vos, J., Thykjaer, T., Zhan, F., Fiol, G., Costes, V., Reme, T., Legouffe, E., Rossi, J. F., Shaughnessy, J., Jr., Orntoft, T. F., and Klein, B. Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. [See comments.]. Blood, 100: 1113-1122, 2002.
65. Claudio, J. O., Masih-Khan, E., Tang, H., Goncalves, J., Voralia, M., Li, Z. H., Nadeem, V., Cukerman, E., Francisco-Pabalan, O., Liew, C. C., Woodgett, J. R., and Stewart, A. K. A molecular compendium of genes expressed in multiple myeloma. Blood, 100: 2175-2186, 2002.
66. Magrangeas, F., Nasser. V., Avet-Loiseau, H., Loriod, B., Decaux, O., Granjeaud, S., Bertucci, F., Birnbaum, D., Nguyen, C., Harousseau, J-L., Bataille, R., Houlgatte, R., and Minvielle, S. Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood, 101: 4998-5006, 2003.
67. Latreille, J., Barlogie, B., Johnston, D., Drewinko, B., and Alexanian, R. Ploidy and proliferative characteristics in monoclonal gammopathies. Blood, 59: 43-51, 1982.
68. Zandecki, M., Bernardi, F., Lai, J., Facon, T., Izydorczyk, V., Bauters, F., and Cosson, A. Image analysis in multiple myeloma at diagnosis. Correlation with cytogenetic study. Cancer Genet. Cytogenet., 74: 115-119, 1994.
69. Zandecki, M., Lai, J. L., Genevieve, F., Bernardi, F., Volle-Remy, H., Blanchet, O., Francois, M., Cosson, A., Bauters, F., and Facon, T. Several cytogenetic subclones may be identified within plasma cells from patients with monoclonal gammopathy of undetermined significance, both at diagnosis and during the indolent course of this condition. Blood, 90: 3682-3690, 1997.
70. Drach, J., Angerler, J., Schuster, J., Thalhammer, R., Jager, U., Geissler, K., Lechner K., Ludwig, H., and Huber, H. Clonal chromosomal aberrations in plasma cells from patients with monoclonal gammopathy of undetermined significance (MGUS). Proc Am. Assoc. Cancer Res., 36: 144, 1995.
71. Smadja, N. V., Bastard, C., and Brgaudeau, C. Primary plasma cell leukemia and multiple myeloma: one or two diseases according to the methodology [Letter; comment]. Blood, 94: 3607-3609, 1999.
72. Greipp, P. R., Trendle, M. C., Leong, T., Oken, M. M., Kay, N. E., Van Ness, B., and Kyle, R. A. Is flow cytometric DNA content hypodiploidy prognostic in multiple myeloma? Leuk. Lymphoma., 35: 83-89, 1999.
73. Orfao, A., Garcia-Sanz, R., Lopez-Berges, M. C., Belen Vidriales, M., Gonzalez, M., Caballero, M. D., and San Miguel, J. F. A new method for the analysis of plasma cell DNA content in multiple myeloma samples using a CD38/propidium iodide double staining technique. Cytometry, 17: 332-339, 1994.
74. Latreille, J., Barlogie, B., Dosik, G., Johnston, D. A., Drewinko, B., and Alexanian, R. Cellular DNA content as a marker of human multiple myeloma. Blood, 55: 403-408, 1980.
75. Fonseca, R., Debes-Marun, C., Picken, E., Dewald, G., Bryant, S., Winkler, J., Blood, E., Oken, M. M., Santana-Dávila, R., González-Paz, N., Kyle, R., Gertz, M., Dispenzieri, A., Lacy, M., and Greipp, P. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood, 102: 2562-2567, 2003.
76. Smadja, N. V., Leroux, D., Soulier, J., Dumont, S., Arnould, C., Taviaux, S., Taillemite, J. L., and Bastard, C. Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid patients. Genes Chromosomes Cancer, 38: 234-239, 2003.
77. Perez-Simon, J. A., Garcia-Sanz, R., Tabernero, M. D., Almeida, J., Gonzalez, M., Fernandez-Calvo, J., Moro, M. J., Hernandez, J. M., San Miguel, J. F., and Orfao, A. Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes. Blood, 91: 3366-3371, 1998.
78. Smith, L., Barlogie, B., and Alexanian, R. Biclonal and hypodiploid multiple myeloma. Am. J. Med., 80: 841-843, 1986.
79. Calasanz, M. J., Cigudosa, J. C., Odero, M. D., Garcia-Foncillas, J., Marin, J., Ardanaz, M. T., Rocha, E., and Gullon, A. Hypodiploidy and 22q11 rearrangements at diagnosis are associated with poor prognosis in patients with multiple myeloma. Br. J. Haematol., 98: 418-425, 1997.
80. Fassas, A. B., Spencer, T., Sawyer, J., Zangari, M., Lee, C. K., Anaissie, E., Muwalla, F., Morris, C., Barlogie, B., and Tricot, G. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br. J. Haematol., 118: 1041-1047, 2002.
81. Drach, J., Kaufmann, H., Urbauer, E., Schreiber, S., Ackermann, J., and Huber, H. The biology of multiple myeloma. [Review]. J. Cancer Res. Clin. Oncol., 126: 441-447, 2000.
82. Fonseca, R., Bailey, R., Ahmann, G., Aguayo, P., Jalal, S., Rajkumar, S., Kyle, R., Gertz, M., Dispenzieri, A., Lust, J., Lacy, M., Witzig, T., Greipp, P., and Dewald, G. Translocations involving 14q32 are common in patients with the monoclonal gammopathy of undetermined significance. Blood, in press, 2003.
83. Zojer, N., Konigsberg, R., Ackermann, J., Fritz, E., Dallinger, S., Kromer, E., Kaufmann, H., Riedl, L., Gisslinger, H., Schreiber, S., Heinz, R., Ludwig, H., Huber, H., and Drach, J. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood, 95: 1925-1930, 2000.
84. Facon, T., Avet-Loiseau, H., Guillerm, G., Moreau, P., Geneviève, F., Zandecki, M., Laï, J., Leleu, X., Jouet, J., Bauters, F., Harousseau, J., Bataille, R., Mary, J. Y., and Intergroupe Francophone du Myelome. Chromosome 13 abnormalities identified by FISH analysis and serum β-2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood, 97: 1566-1571, 2001.
85. Carlebach, M., Amiel, A., Gaber, E., Radnay, J., Manor, Y., Fejgin, M., and Lishner, M. Multiple myeloma: monoallelic deletions of the tumor suppressor genes TP53 and RB1 in long-term follow-up. Cancer Genet. Cytogenet., 117: 57-60, 2000.
86. Shaughnessy, J., Tian, E., Sawyer, J., Bumm, K., Landes, R., Badros, A., Morris, C., Tricot, G., Epstein, J., and Barlogie, B. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood, 96: 1505-1511, 2000.
87. Desikan, R., Barlogie, B., Sawyer, J., Ayers, D., Tricot, G., Badros, A., Zangari, M., Munshi, N. C., Anaissie, E., Spoon, D., Siegel, D., Jagannath, S., Vesole, D., Epstein, J., Shaughnessy, J., Fassas, A., Lim, S., Roberson, P., and Crowley, J. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood, 95: 4008-4010, 2000.
88. Shaughnessy, J., Jr., Tian, E., Sawyer, J., McCoy, J., Tricot, G., Jacobson, J., Anaissie, E., Zangari, M., Fassas, A., Muwalla, F., Morris, C., and Barlogie, B. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. Br. J. Haematol., 120: 44-52, 2003.
89. Shaughnessy, J., Jacobson, J., Sawyer, J., McCoy, J., Fassas, A., Zhan, F., Bumm, K., Epstein, J., Anaissie, E., Jagannath, S., Vesole, D., Siegel, D., Desikan, R., Munshi, N., Badros, A., Tian, E., Zangari, M., Tricot, G., Crowley, J., and Barlogie, B. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy 1: interpretation in the context of global gene expression. Blood, 101: 3849-3856, 2003.
90. Tricot, G., Sawyer, J. R., Jagannath, S., Desikan, K. R., Siegel, D., Naucke, S., Mattox, S., Bracy, D., Munshi, N., and Barlogie, B. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J. Clin. Oncol., 15: 2659-2666, 1997.
91. Moreau, P., Facon, T., Leleu, X., Morineau, N., Huyghe, P., Harousseau, J. L., Bataille, R., and Avet-Loiseau, H. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood, 100: 1579-1583, 2002.
92. Schreiber, S., Ackermann, J., Obermair, A., Kaufmann, H., Urbauer, E., Aletaha, K., Gisslinger, H., Chott, a., Huber, H., and Drach, J. Multiple myeloma with deletion of chromosome 13q is characterized by increased bone marrow neovascularization. Br. J. Haematol., 110: 605-609, 2000.
93. Bergsagel, P. L., Chesi, M., Brents, L. A., and Kuehl, W. M. Translocations into IgH switch regions - the genetic hallmark of multiple myeloma. Blood, 86: 223-223, 1995.
94. Bergsagel, P. L., Chesi, M., Nardini, E., Brents, L. A., Kirby, S. L., and Kuehl, W. M. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc. Natl. Acad. Sci. USA, 93: 13931-13936, 1996.
95. Nishida, K., Tamura, A., Nakazawa, N., Ueda, Y., Abe, T., Matsuda, F., Kashima, K., and Taniwaki, M. The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Blood, 90: 526-534, 1997.
96. Shou, Y., Martelli, M. L., Gabrea, A., Qi, Y., Brents, L. A., Roschke, A., Dewald, G., Kirsch, I. R., Bergsagel, P. L., and Kuehl, W. M. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc. Natl. Acad. Sci. USA, 97: 228-233, 2000.
97. Avet-Loiseau, H., Gerson, F., Magrangeas, F., Minvielle, S., Harousseau, J. L., and Bataille, R. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood, 98: 3082-3086, 2001.
98. Ried, K., Finnis, M., Hobson, L., Mangelsdorf, M., Dayan, S., Nancarrow, J. K., Woollatt, E., Kremmidiotis, G., Gardner, A., Venter, D., Baker, E., and Richards, R. I. Common chromosomal fragile site FRA16D sequence: identification of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells. Hum. Mol. Genet., 9: 1651-1663, 2000.
99. Krummel, K. A., Roberts, L. R., Kawakami, M., Glover, T. W., and Smith, D. I. The characterization of the common fragile site FRA16D and its involvement in multiple myeloma translocations. Genomics, 69: 37-46, 2000.
100. Hallek, M., Leif Bergsagel, P., and Anderson, K. C. Multiple myeloma: increasing evidence for a multistep transformation process. Blood, 91: 3-21, 1998.
101. Willis, T. G., and Dyer, M. J. The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. Blood, 96: 808-822, 2000.
102. Avet-Loiseau, H., Daviet, A., Brigaudeau, C., Callet-Bauchu, E., Terre, C., Lafage-Pochitaloff, M., Desangles, F., Ramond, S., Talmant, P., and Bataille, R. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique. Blood, 97: 822-825, 2001.
103. Bergsagel, P., and Kuehl, W. Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma. Immunol Rev., 194: 96-104, 2003.
104. Shaughnessy, J., Jr., Gabrea, A., Qi, Y., Brents, L., Zhan, F., Tian, E., Sawyer, J., Barlogie, B., Bergsagel, P. L., and Kuehl, M. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood, 98: 217-223, 2001.
105. Malgeri, U., Baldini, L., Perfetti, V., Fabris, S., Vignarelli, M. C., Colombo, G., Lotti, V., Compasso, S., Bogni, S., Lombardi, L., Maiolo, A. T., and Neri, A. Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts. Cancer Res., 60: 4058-4061, 2000.
106. Chesi, M., Bergsagel, P. L., Brents, L. A., Smith, C. M., Gerhard, D. S., and Kuehl, W. M. Dysregulation of cyclin D1 by translocation into an IgH γ switch region in two multiple myeloma cell lines. Blood, 88: 674-681, 1996.
107. Fonseca, R., Witzig, T. E., Gertz, M. A., Kyle, R. A., Hoyer, J. D., Jalal, S. M., and Greipp, P. R. Multiple myeloma and the translocation t(11;14)(q13;q32) - a report on 13 cases. Br. J. Haematol., 101: 296-301, 1998.
108. Harrison, C., Mazullo, H., Cheung, K., Mehta, A., Lachmann, H., Hawkins, P., and Orchard, K. Chromosomal abnormalities in systemic amyloidosis. In: Proceedings of the VIII International Myeloma Workshop, Banff, Alberta, Canada, 2001, p. P18.
109. Janssen, J. W., Vaandrager, J. W., Heuser, T., Jauch, A., Kluin, P. M., Geelen, E., Bergsagel, P. L., Kuehl, W. M., Drexler, H. G., Otsuki, T., Bartram, C. R., and Schuuring, E. Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13;q32). Blood, 95: 2691-2698, 2000.
110. Vaandrager, J. W., Kluin, P., and Schuuring, E. The t(11;14) (q13;q32) in multiple myeloma cell line KMS12 has its 11q13 breakpoint 330 kb centromeric from the cyclin D1 gene [Letter]. Blood, 89: 349-350, 1997.
111. Meeus, P., Stul, M. S., Mecucci, C., Cassiman, J. J., and Van den Berghe, H. Molecular breakpoints of t(11;14)(q13;q32) in multiple myeloma. Cancer Genet Cytogenet., 83: 25-27, 1995.
112. Ronchetti, D., Finelli, P., Richelda, R., Baldini, L., Rocchi, M., Viggiano, L., Cuneo, A., Bogni, S., Fabris, S., Lombardi, L., Maiolo, A., and Neri, A. Molecular analysis of 11q13 breakpoints in multiple myeloma. Blood, 93: 1330-1337, 1999.
113. Raynaud, S. D., Bekri, S., Leroux, D., Grosgeorge, J., Klein, B., Bastard, C., Gaudray, P., and Simon, M. P. Expanded range of 11q13 breakpoints with differing patterns of cyclin D1 expression in B-cell malignancies. Genes Chromosomes Cancer, 8: 80-87, 1993.
114. Hoyer, J. D., Hanson, C. A., Fonseca, R., Greipp, P. R., Dewald, G. W., and Kurtin, P. J. The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study. Am. J. Clin. Pathol., 113: 831-837, 2000.
115. Vasef, M. A., Medeiros, L. J., Yospur, L. S., Sun, N. C., McCourty, A., and Brynes, R. K. Cyclin D1 protein in multiple myeloma and plasmacytoma: an immunohistochemical study using fixed, paraffin-embedded tissue sections. Mod. Pathol., 10: 927-932, 1997.
116. Rosenwald, A., Wright, G., Wiestner, A., Chan, W. C., Connors, J. M., Campo, E., Gascoyne, R. D., Grogan, T. M., Muller-Hermelink, H. K., Smeland, E. B., Chiorazzi, M., Giltnane, J. M., Hurt, E. M., Zhao, H., Averett, L., Henrickson, S., Yang, L., Powell, J., Wilson, W. H., Jaffe, E. S., Simon, R., Klausner, R. D., Montserrat, E., Bosch, F., Greiner, T. C., Weisenburger, D. D., Sanger, W. G., Dave, B. J., Lynch, J. C., Vose, J., Armitage, J. O., Fisher, R. I., Miller, T. P., LeBlanc, M., Ott, G., Kvaloy, S., Holte, H., Delabie, J., and Staudt, L. M. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell., 3: 185-197, 2003.
117. Konigsberg, R., Zojer, N., Ackermann, J., Kromer, E., Kittler, H., Fritz, E., Kaufmann, H., Nosslinger, T., Riedl, L., Gisslinger, H., Jager, U., Simonitsch, I., Heinz, R., Ludwig, H., Huber, H., and Drach, J. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J. Clin. Oncol., 18: 804-812, 2000.
118. Robillard, N., Avet-Loiseau, H., Garand, R., Moreau, P., Pineau, D., Rapp, M-J., Harousseau, J-L., and Bataille, R. CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood, 102: 1070-1071, 2003.
119. Avet-Loiseau, H., Garand, R., Lode, L., Harousseau, J-L., and Bataille, R. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood, 101: 1570-1571, 2003.
120. Chesi, M., Nardini, E., Lim, R., Smith, K., Kuehl, W., and Bergsagel, P. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood, 92: 3025-3034, 1998.
121. Richelda, R., Ronchetti, D., Baldini, L., Cro, L., Viggiano, L., Marzella, R., Rocchi, M., Otsuki, T., Lombardi, L., Maiolo, A. T., and Neri, A. A novel chromosomal translocation t(4;14)(p16.3;q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood, 90: 4062-4070, 1997.
122. Intini, D., Baldini, L., Fabris, S., Lombardi, L., Ciceri, G., Maiolo, A. T., and Neri, A. Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14). Br. J. Haematol., 114: 362-364, 2001.
123. Chesi, M., Brents, L. A., Ely, S. A., Bais, C., Robbiani, D. F., Mesri, E. A., Kuehl, W. M., and Bergsagel, P. L. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood, 97: 729-736, 2001.
124. Ronchetti, D., Greco, A., Compasso, S., Colombo, G., Dell'Era, P., Otsuki, T., Lombardi, L., and Neri, A. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations. Oncogene, 20: 3553-3562, 2001.
125. Perfetti, V., Coluccia, A., Intini, D., Malgeri, U., Colli Vignarelli, M., Casarini, S., Merlini, G., and Neri, A. Translocation t(4;14)(p16.3;q32) is a recurrent genetic lesion in primary amyloidosis. Leukemia (Baltimore), 158: 1599-1603, 2001.
126. Hanamura, I., Iida, S., Akano, Y., Hayami, Y., Kato, M., Miura, K., Harada, S., Banno, S., Wakita, A., Kiyoi, H., Naoe, T., Shimizu, S., Sonta, S. I., Nitta, M., Taniwaki, M., and Ueda, R. Ectopic expression of MAFB gene in human myeloma cells carrying (14;20)(q32;q11) chromosomal translocations. Jpn J Cancer Res., 92: 638-644, 2001.
127. Iida, S., Rao, P. H., Butler, M., Corradini, P., Boccadoro, M., Klein, B., Chaganti, R. S., and Dalla-Favera, R. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat. Genet., 17: 226-230, 1997.
128. Yoshida, S., Nakazawa, N., Iida, S., Hayami, Y., Sato, S., Wakita, A., Shimizu, S., Taniwaki, M., and Ueda, R. Detection of MUM1/IRF4-IgH fusion in multiple myeloma. Leukemia (Baltimore), 13: 1812-1816, 1999.
129. Liu, P., Leong, T., Quam, L., Billadeau, D., Kay, N. E., Greipp, P., Kyle, R. A., Oken, M. M., and Van Ness, B. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood, 88: 2699-2706, 1996.
130. Bezieau, S., Devilder, M. C., Avet-Loiseau, H., Mellerin, M. P., Puthier, D., Pennarun, E., Rapp, M. J., Harousseau, J. L., Moisan, J. P., and Bataille, R. High incidence of N- and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum. Mutat., 18: 212-224, 2001.
131. Bezieau, S., Avet-Loiseau, H., Moisan, J. P., and Bataille, R. Activating Ras mutations in patients with plasma-cell disorders: a reappraisal. Blood, 100: 1101-1102, 2003.
132. Corradini, P., Ladetto, M., Voena, C., Palumbo, A., Inghirami, G., Knowles, D. M., Boccadoro, M., and Pileri, A. Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. Blood, 81: 2708-2713, 1993.
133. Neri, A., Murphy, J. P., Cro, L., Ferrero, D., Tarella, C., Baldini, L., and Dalla-Favera, R. Ras oncogene mutation in multiple myeloma. J. Exp. Med., 170: 1715-1725, 1989.
134. Matozaki, S., Nakagawa, T., Nakao, Y., and Fujita, T. RAS gene mutations in multiple myeloma and related monoclonal gammopathies. Kobe J. Med. Sci., 37: 35-45, 1991.
135. Crowder, C., Kopantzev, E., Williams, K., Lengel, C., Miki, T., and Rudikoff, S. An unusual H-Ras mutant isolated from a human multiple myeloma line leads to transformation and factor-independent cell growth. Oncogene, 22: 649-659, 2003.
136. Drach, J., Ackermann, J., Fritz, E., Kromer, E., Schuster, R., Gisslinger, H., DeSantis, M., Zojer, N., Fiegl, M., Roka, S., Schuster, J., Heinz, R., Ludwig, H., and Huber, H. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood, 92: 802-809, 1998.
137. Schultheis, B., Kramer, A., Willer, A., Hegenbart, U., Goldschmidt, H., and Hehlmann, R. Analysis of p73 and p53 gene deletions in multiple myeloma. Leukemia (Baltimore), 13: 2099-2103, 1999.
138. Mazars, G. R., Portier, M., Zhang, X. G., Jourdan, M., Bataille, R., Theillet, C., and Klein, B. Mutations of the p53 gene in human myeloma cell lines. Oncogene, 7: 1015-1018, 1992.
139. Corradini, P., Inghirami, G., Astolfi, M., Ladetto, M., Voena, C., Ballerini, P., Gu, W., Nilsson, K., Knowles, D. M., Boccadoro, M., Pileri, A., and Dalla-Favera, R. Inactivation of tumor suppressor genes, p53 and Rbl, in plasma cell dyscrasias. Leukemia (Baltimore), 8: 758-767, 1994.
140. Neri, A., Baldini, L., Trecca, D., Cro, L., Polli, E., and Maiolo, A. T. p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood, 81: 128-135, 1993.
141. Preudhomme, C., Facon, T., Zandecki, M., Vanrumbeke, M., Lai, J. L., Nataf, E., Loucheux, L. M. H., Kerckaert, J. P., and Fenaux, P. Rare occurrence of p53 gene mutations in multiple myeloma. Br. J. Haematol., 81: 440-443, 1992.
142. Ackermann, J., Meidlinger, P., Zojer, N., Gisslinger, H., Ludwig, H., Huber, H., and Drach, J. Absence of p53 deletions in bone marrow plasma cells of patients with monoclonal gammopathy of undetermined significance. Br. J. Haematol., 103: 1161-1163, 1998.
143. Teoh, G., Urashima, M., Ogata, A., Chauhan, D., DeCaprio, J. A., Treon, S. P., Schlossman, R. L., and Anderson, K. C. MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells. Blood, 90: 1982-1992, 1997.
144. Potter, M. Perspectives on the origins of multiple myeloma and plasmacytomas in mice. Hematol. Oncol. Clin. North Am., 6: 211-223, 1992.
145. Gado, K., Silva, S., Paloczi, K., Domjan, G., and Falus, A. Mouse plasmacytoma: an experimental model of human multiple myeloma. [Review]. Haematologica, 86: 227-236, 2001.
146. Zhang, S-L., DuBois, W., Ramsay, E. S., Bliskovski, V., Morse, H. C., III, Taddesse-Heath, L., Vass, W. C., DePinho, R. A., and Mock, B. A. Efficiency alleles of the Pctr1 modifier locus for plasmacytoma susceptibility. Mol. Cell. Biol., 21: 310-318, 2001.
147. Dilworth, D., Liu, L., Stewart, A. K., Berenson, J. R., Lassam, N., and Hogg, D. Germline CDKN2A mutation implicated in predisposition to multiple myeloma. Blood, 95: 1869-1871, 2000.
148. Gonzalez, M., Mateos, M. V., Garcia-Sanz, R., Balanzategui, A., Lopez-Perez, R., Chillon, M. C., Gonzalez, D., Alaejos, I., and San Miguel, J. F. De novo methylation of tumor suppressor gene p16/INK4a is a frequent finding in multiple myeloma patients at diagnosis. Leukemia (Baltimore), 14: 183-187, 2000.
149. Uchida, T., Kinoshita, T., Ohno, T., Ohashi, H., Nagai, H., and Saito, H. Hypermethylation of p16 INK4A gene promoter during the progression of plasma cell dyscrasia. Leukemia (Baltimore), 15: 157-165, 2001.
150. Ng, M. H., Wong, I. H., and Lo, K. W. DNA methylation changes and multiple myeloma. [Review]. Leuk. Lymphoma, 34: 463-472, 1999.
151. Lo, Y. M., Wong, I. H., Zhang, J., Tein, M. S., Ng, M. H., and Hjelm, N. M. Quantitative analysis of aberrant p16 methylation using real-time quantitative methylation-specific polymerase chain reaction. Cancer Res., 59: 3899-3903, 1999.
152. Arora, T., and Jelinek, D. F. Differential myeloma cell responsiveness to interferon-α correlates with differential induction of p19(Ink4d) and cyclin D2 expression. J. Biol. Chem., 273: 11799-11805, 1998.
153. Mateos, M. V., Garcia-Sanz, R., Lopez-Perez, R., Moro, M. J., Ocio, E., Hernandez, J., Megido, M., Caballero, M. D., Fernandez-Calvo, J., Barez, A., Almeida, J., Orfao, A., Gonzalez, M., and San Miguel, J. F. Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. Br. J. Haematol., 118: 1034-1040, 2002.
154. Guillerm, G., Gyan, E., Wolowiec, D., Facon, T., Avet-Loiseau, H., Kuliczkowski, K., Bauters, F., Fenaux, P., and Quesnel, B. p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance. Blood, 98: 244-246, 2001.
155. Morse, L., Chen, D., Franklin, D., Xiong, Y., and Chen-Kiang, S. Induction of cell cycle arrest and B cell terminal differentiation by CDK inhibitor p18(INK4c) and IL-6. Immunity, 6: 47-56, 1997.
156. Kulkarni, M. S., Daggett, J. L., Bender, T. P., Kuehl, W. M., Bergsagel, P. L., and Williams, M. E. Frequent inactivation of the cyclin-dependent kinase inhibitor p18 by homozygous deletion in multiple myeloma cell lines: ectopicp18 expression inhibits growth and induces apoptosis. Leukemia (Baltimore), 16: 127-134, 2002.
157. Zandecki, M., Facon, T., Preudhomme, C., Vanrumbeke, M., Vachee, A., Quesnel, B., Lai, J. L., Cosson, A., and Fenaux, P. The retinoblastoma gene (RB-1) status in multiple myeloma: a report on 35 cases. Leuk Lymphoma, 18: 497-503, 1995.
158. Juge-Morineau, N., Harousseau, J. L., Amiot, M., and Bataille, R. The retinoblastoma susceptibility gene RB-1 in multiple myeloma. [Review]. Leuk. Lymphoma, 24: 229-237, 1997.
159. Hyun, T., Yam, A., Pece, S., Xie, X., Zhang, J., Miki, T., Gutkind, J. S., and Li, W. Loss of PTEN expression leading to high Akt activation in human multiple myelomas. Blood, 96: 3560-3568, 2000.
160. Ge, N., and Rudikoff, S. Expression of PTEN in PTEN-deficient multiple myeloma cells abolishes tumor growth in vivo. Oncogene, 19: 4091-4095, 2000.
161. Crews, S., Barth, R., Hood, L., Prehn, J., and Calame, K. Mouse c-myc oncogene is located on chromosome 15 and translocated to chromosome 12 in plasmacytomas. Science (Wash. DC), 218: 1319-1321, 1982.
162. Stanton, L. W., Watt, R., and Marcu, K. B. Translocation, breakage and truncated transcripts of c-myc oncogene in murine plasmacytomas. Nature (Lond.), 303: 401-406, 1983.
163. Keath, E. I., Kelekar, A., and Cole, M. D. Transcriptional activation of the translocated c-myc oncogene in mouse plasmacytomas: similar RNA levels in tumor and proliferating normal cells. Cell, 37: 521-528, 1984.
164. Piccoli, S. P., Caimi, P. G., and Cole, M. D. A conserved sequence at c-myc oncogene chromosomal translocation breakpoints in plasmacytomas. Nature (Lond.), 310: 327-330, 1984.
165. Erikson, J., Miller, D. A., Miller, O. J., Abcarian, P. W., Skurla, R. M., Mushinski, J. F., and Croce, C. M. The c-myc oncogene is translocated to the involved chromosome 12 in mouse plasmacytoma. Proc. Natl. Acad. Sci. USA, 82: 4212-4216, 1985.
166. Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D., and Brinster, R. L. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature (Lond.), 318: 533-538, 1985.